Skip to main content
GLP-1 medicines are changing the way employers and health plans think about pharmacy benefits. These medications, once primarily associated with diabetes and weight management, are now being approved for new treatment purposes, and that’s changing the conversation around coverage.
What’s New?
Wegovy has just been approved by the FDA to treat MASH/NASH (Metabolic or Non-Alcoholic Steatohepatitis), a serious liver condition that affects about 6% of people in the U.S. This approval matters because the only other treatment for MASH/NASH is more expensive and less effective. Covering Wegovy can help improve patient outcomes while reducing total plan spend, making it a win for both health and cost management.
Why This Changes the Conversation
As Stacey Bane, Director of Pharmacy Solutions at Houchens Insurance Group, explains: “Not every GLP-1 conversation has to be exclusion. Sometimes covering more is the smarter move.” This marks a significant shift from the old approach of saying “no” to GLP-1s across the board. Instead, employers and health plans need to identify when coverage makes sense, both clinically and financially.
Making Smarter Decisions
The pharmacy landscape is evolving quickly, and with each new FDA approval, the stakes get higher. “As the pharmacy landscape evolves, our job isn’t to say ‘yes’ or ‘no’ to coverage- it’s to help employers make the right decisions, backed by evidence,” says Bane. That means looking at the data, understanding the impact on health outcomes, and finding ways to manage costs without sacrificing care.
Rethinking your plan is an opportunity to improve care and manage costs at the same time. Our team is here to talk about how smart GLP-1 coverage can transform your pharmacy benefits strategy and what plan is best for you.
